FOLR1 and ovarian cancer: In this study, we developed five NIR-PIT agents by conjugating scFv-SNAP-tag fusion proteins with BG-modified IRdye700 to target ovarian cancer cells, which expressed cell surface antigens epidermal growth factor receptor (EGFR), Her2, FOLR1, TROP2, and TF.